Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5% KOH solution vs placebo for mild to moderate actinic keratosis
2024-514277-21-00Phase 3Authorised
- Sponsor
- InfectoPharm
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Solcera 5% potassium hydroxide solution with Placebo (preserved water) (2 arms). Planned start Jan 2025; status: authorised.
02
Drugs
potassium hydroxide
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2024-514277-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514277-21-00.